J Endocrinol Metab

Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access

Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc

Journal website http://www.jofem.org

Original Article

Volume 5, Number 6, December 2015, pages 333-336

Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco

Tables

**Table 1.** Characteristics of the Study Population at Inclusion (Baseline)
Characteristic
All values shown are n (%), or mean ± SD.
Sex
Male/female	220/274 (44.5/55.5)
Age (years)	57.5 ± 10.3
Age group (years)
18 - 40	15 (3.1)
41 - 50	98 (20.0)
51 - 60	185 (37.7)
61 - 70	133 (27.1)
> 70	60 (12.2)
Duration of diabetes (years)	9.8 ± 6.1
Body mass index
< 25 kg/m²	118 (25.3)
25 - 30 kg/m²	230 (49.1)
> 30 kg/m²	120 (25.6)
Insulin therapy
Initiation of insulin glargine	388 (78.1)
Modification of insulin (change to insulin glargine)	109 (21.9)

**Table 2.** Changes in Antidiabetic Treatments Over the 6-Month Study Period
	Week 12 (visit 2)	Week 26 (visit 3)
Results are shown as n (%). OAD: antidiabetic drugs.
Total number of OAD changes	150/477 (31.4)	57/454 (12.6)
OAD stopped	98/477 (20.5)	37/454 (8.1)
OAD added	87/477 (18.2)	31/442 (7.0)
Sulphonylureas stopped	48/477 (10.1)	16/454 (3.5)
Biguanides stopped	28/477 (5.9)	16/454 (3.5)
Insulin glargine
Dose changed	398/484 (82.2)	225/470 (47.9)
Rapid insulin added	45/484 (9.3)	33/470 (7.0)

**Table 3.** Evolution of Efficacy Outcome Measures During the 6-Month Study Period
	Inclusion	Week 12	Week 26	P
	Inclusion	Week 12	Week 26	I-W12	I-W26
Values shown are n (%), or mean ± SD. FBG: fasting blood glucose.
HbA1c ≤ 7%	0 (0)	55 (11.5)	149 (32.0)
HbA1c (%)	9.37±1.14	8.08±1.03	7.43±0.87	< 0.001	< 0.001
FBG (mg/dL)	237.5 ± 66.9	154.4 ± 47.7	129.5 ± 35.1	< 0.001	< 0.001